Machine learning uncovers potent immunomodulators for vaccines and immunotherapy

Small molecules called immunomodulators can help create more effective vaccines and stronger immunotherapies to treat cancer.

Edgewood’s $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year

Plus, news about bluebird bio, Q32 Bio and Aquestive Therapeutics: Edgewood Oncology’s $20M Series A: The Brookline, MA-based biotech plans to use the money to

March 27, 2024

Bluebird bio handed negative opinion from federal oversight agency for fertility support program

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 23, 2024

Widespread cannabis use linked to increase in psychiatric disorders, UMSOM review finds

The widespread use of cannabis (marijuana) and its increased potency are associated with a rise in cannabis-related psychiatric conditions, according to a new University of

December 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.